Healthcare stocks face uncertainty as the political landscape shifts with the impending Democratic control of Congress. Jared Holz, a healthcare analyst at Mizuho, indicates that the sector might experience legislative gridlock in the coming years, which could hinder growth opportunities. He expressed caution regarding investment in pharmaceutical stocks, noting that they are now trading at higher valuations than technology stocks for the first time in two decades. Instead, Holz recommends focusing on medical technology companies as a potentially more promising investment avenue.
The State Street Health Care Select ETF (XLV) saw a 3% increase immediately following the recent elections, diverging from historical patterns where such categories typically do not perform in unison. However, this uptick was short-lived as healthcare stocks faced a sell-off the following week.
Holz suggests that the true potential for healthcare investments may arise if a Democrat wins the presidency in 2028, leading to the reversal of certain policies instituted during the Trump administration. He emphasizes that the performance of healthcare stocks heavily depends on maintaining Democratic control in both chambers of Congress. He advises investors to view each subsector individually and remains skeptical about the possibility of significant regulatory changes in the near term. The State Street Health Care Select ETF concluded the week nearly flat, yet it has gained approximately 32% since January 2025, outperforming the S&P 500 by nearly nine percentage points.
Why this story matters: The political climate significantly influences healthcare investments, impacting stock performance and regulatory frameworks.
Key takeaway: Investors should consider the healthcare sector’s varied subsectors and potential regulatory changes before making investment decisions.
Opposing viewpoint: Some analysts believe healthcare stocks could thrive regardless of political shifts, driven by innovation and demand in the sector.
